p53: Prospettive per la terapia genica dei tumori

S. Soddu, A. Sacchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To evaluate the prospects for cancer gene therapy through restoration of wild-type p53 (wt-p53) protein expression and/or function. Design: To review the most significant data reported in the literature with particular attention in dissecting the biological questions that are still open and need to be clarified to improve TP53-based gene therapy. Results: Considerable experimental evidence obtained in vitro and in vivo indicates that wt-p53 protein can suppress the transformed phenotype of several types of cancer in humans as well as other species. Wt-p53 protein suppress transformation by inducing different biological effects including maintenance of genomic stability, inhibition of cell proliferation, induction of apoptosis, differentiation or senescence. All these findings have rendered p53 a potential helpful target for therapy of many types of human cancers. Conclusions: Different experimental strategies based on i) TP53 gene-replacement, ii) restoration of wt-p53 activity, iii) replication of defective lytic viruses specifically in altered p53-expressing tumors, have given promising results in vitro and, in some cases also in vivo. At present, a few phase one clinical trials have been started for some of the gene-replacement strategies.

Original languageItalian
Pages (from-to)289-295
Number of pages7
JournalClinica Terapeutica
Volume149
Issue number4
Publication statusPublished - 1998

ASJC Scopus subject areas

  • Medicine(all)

Cite this

p53 : Prospettive per la terapia genica dei tumori. / Soddu, S.; Sacchi, A.

In: Clinica Terapeutica, Vol. 149, No. 4, 1998, p. 289-295.

Research output: Contribution to journalArticle

Soddu, S & Sacchi, A 1998, 'p53: Prospettive per la terapia genica dei tumori', Clinica Terapeutica, vol. 149, no. 4, pp. 289-295.
Soddu, S. ; Sacchi, A. / p53 : Prospettive per la terapia genica dei tumori. In: Clinica Terapeutica. 1998 ; Vol. 149, No. 4. pp. 289-295.
@article{7158f331f82a42bea3ad60fc9d111025,
title = "p53: Prospettive per la terapia genica dei tumori",
abstract = "Purpose: To evaluate the prospects for cancer gene therapy through restoration of wild-type p53 (wt-p53) protein expression and/or function. Design: To review the most significant data reported in the literature with particular attention in dissecting the biological questions that are still open and need to be clarified to improve TP53-based gene therapy. Results: Considerable experimental evidence obtained in vitro and in vivo indicates that wt-p53 protein can suppress the transformed phenotype of several types of cancer in humans as well as other species. Wt-p53 protein suppress transformation by inducing different biological effects including maintenance of genomic stability, inhibition of cell proliferation, induction of apoptosis, differentiation or senescence. All these findings have rendered p53 a potential helpful target for therapy of many types of human cancers. Conclusions: Different experimental strategies based on i) TP53 gene-replacement, ii) restoration of wt-p53 activity, iii) replication of defective lytic viruses specifically in altered p53-expressing tumors, have given promising results in vitro and, in some cases also in vivo. At present, a few phase one clinical trials have been started for some of the gene-replacement strategies.",
keywords = "Apoptosis, Chemo- and radio-resistance, Gene therapy, p53 onco-suppressor, Tumor targeting",
author = "S. Soddu and A. Sacchi",
year = "1998",
language = "Italian",
volume = "149",
pages = "289--295",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "4",

}

TY - JOUR

T1 - p53

T2 - Prospettive per la terapia genica dei tumori

AU - Soddu, S.

AU - Sacchi, A.

PY - 1998

Y1 - 1998

N2 - Purpose: To evaluate the prospects for cancer gene therapy through restoration of wild-type p53 (wt-p53) protein expression and/or function. Design: To review the most significant data reported in the literature with particular attention in dissecting the biological questions that are still open and need to be clarified to improve TP53-based gene therapy. Results: Considerable experimental evidence obtained in vitro and in vivo indicates that wt-p53 protein can suppress the transformed phenotype of several types of cancer in humans as well as other species. Wt-p53 protein suppress transformation by inducing different biological effects including maintenance of genomic stability, inhibition of cell proliferation, induction of apoptosis, differentiation or senescence. All these findings have rendered p53 a potential helpful target for therapy of many types of human cancers. Conclusions: Different experimental strategies based on i) TP53 gene-replacement, ii) restoration of wt-p53 activity, iii) replication of defective lytic viruses specifically in altered p53-expressing tumors, have given promising results in vitro and, in some cases also in vivo. At present, a few phase one clinical trials have been started for some of the gene-replacement strategies.

AB - Purpose: To evaluate the prospects for cancer gene therapy through restoration of wild-type p53 (wt-p53) protein expression and/or function. Design: To review the most significant data reported in the literature with particular attention in dissecting the biological questions that are still open and need to be clarified to improve TP53-based gene therapy. Results: Considerable experimental evidence obtained in vitro and in vivo indicates that wt-p53 protein can suppress the transformed phenotype of several types of cancer in humans as well as other species. Wt-p53 protein suppress transformation by inducing different biological effects including maintenance of genomic stability, inhibition of cell proliferation, induction of apoptosis, differentiation or senescence. All these findings have rendered p53 a potential helpful target for therapy of many types of human cancers. Conclusions: Different experimental strategies based on i) TP53 gene-replacement, ii) restoration of wt-p53 activity, iii) replication of defective lytic viruses specifically in altered p53-expressing tumors, have given promising results in vitro and, in some cases also in vivo. At present, a few phase one clinical trials have been started for some of the gene-replacement strategies.

KW - Apoptosis

KW - Chemo- and radio-resistance

KW - Gene therapy

KW - p53 onco-suppressor

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=0032107361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032107361&partnerID=8YFLogxK

M3 - Articolo

C2 - 9866891

AN - SCOPUS:0032107361

VL - 149

SP - 289

EP - 295

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 4

ER -